EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme

Magdalene Joseph iD, Jacob Tharakan, Jemma Proudfoot-Jones, Joseph J Sacco, Andrew Furness iD, David McMahon, Leila Khoja, Lalit Pallan iD, Patricio Serra iD, Dulani Ranatunge, Bode Oladipo, Gemma Clements und 7 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Magdalene Joseph und 18 weiteren Autor:innen. Beteiligte Einrichtung: Mount Vernon Cancer Centre, Northwood, HA6 2RN, United Kingdom. Hauptthemen laut MEDLINE: Uveal Neoplasms, Melanoma. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic uveal melanoma (mUM) carries a poor prognosis, with low response rates to checkpoint inhibitors. The phase III first-line IMCgp100-202 trial established tebentafusp, a bi-specific T cell engager, as the first treatment to demonstrate a survival benefit in mUM. Here, we report retrospective real-world efficacy and toxicity outcomes from the tebentafusp United Kingdom Expanded Access Programme (UK EAP). Patients and methods 115 HLA-A*02:01 positive patients with mUM were treated between July 2021 and June 2023. 10 of 18 UK EAP centres submitted data, and outcomes for 88 patients are reported here. Data was collected on demographics, disease characteristics, survival, and treatment toxicities and analyzed to identify factors impacting on median overall survival (mOS), median progression-free survival (mPFS), occurrence of cytokine release syndrome (CRS) and grade 3/4 rash.

Results

71% of patients were treated in the first-line setting, with 94% having liver metastases. At a median follow-up of 12 months (range 0 to 34), mOS was 21 months (95% CI, 17 to NR), and mPFS was 2.76 months (95% CI, 2.53-3.22). The 12-month overall survival rate was 75% (95% CI, 66.11-85.6). Lower lactate dehydrogenase (LDH) and lower liver metastatic burden showed a trend towards improved overall survival, with baseline LDH ≥2× ULN conferring a very poor prognosis. Lower liver metastatic burden also associated with reduced frequency of CRS. No ≥ grade 3 toxicity was observed beyond dose 5.

Conclusion

Tebentafusp on the UK EAP showed comparable real-world efficacy to the phase III first-line trial data, with manageable toxicities having implications for resource planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uveal NeoplasmsMelanomaHumansFemaleMaleUveal MelanomaMiddle AgedUnited KingdomAgedAdultRetrospective StudiesAged, 80 and overNeoplasm Metastasis

Stichwörter der Autor:innen

ImmTACbi-specific T-cell engagerexpanded accessmetastatic uveal melanomareal-worldtebentafusptoxicity

Autor:innen und Institutionen

  • Mount Vernon Cancer Centre, Northwood, HA6 2RN, United Kingdom.
  • Clatterbridge Cancer Centre, Wirral, CH63 4JY, United Kingdom.
  • The Royal Marsden Hospital, London, SW3 6JJ, United Kingdom.
  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2GW, United Kingdom.
  • The Christie Hospital, Manchester, M20 4BX, United Kingdom.
  • Castle Hill Hospital, Cottingham, HU16 5JQ, United Kingdom.

ORCID-Profile: Magdalene Joseph, Andrew Furness, Lalit Pallan, Patricio Serra, Lavanya Mariappan

Zitieren

APA

Joseph, M., Tharakan, J., Proudfoot-Jones, J., Sacco, J. J., Furness, A., McMahon, D., Khoja, L., Pallan, L., Serra, P., Ranatunge, D., Oladipo, B., Clements, G., Mariappan, L., Hennah, L., Talbot, T., Nobes, J., Carter, T., Shaw, H., & Nathan, P. (2026). Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme. The Oncologist. https://doi.org/10.1093/oncolo/oyag341

Vancouver

Joseph M, Tharakan J, Proudfoot-Jones J, Sacco JJ, Furness A, McMahon D, et al. Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme. The Oncologist. 2026. doi:10.1093/oncolo/oyag341

BibTeX
@article{Joseph2026,
  author = {Joseph, Magdalene and Tharakan, Jacob and Proudfoot-Jones, Jemma and Sacco, Joseph J and Furness, Andrew and McMahon, David and Khoja, Leila and Pallan, Lalit and Serra, Patricio and Ranatunge, Dulani and Oladipo, Bode and Clements, Gemma and Mariappan, Lavanya and Hennah, Lindsay and Talbot, Toby and Nobes, Jenny and Carter, Thomas and Shaw, Heather and Nathan, Paul},
  title = {Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag341}
}
Kostenlos starten →